FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

1145414000: Product containing precisely carbidopa 25 milligram and levodopa 100 milligram/1 each prolonged-release oral tablet (clinical drug)

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2021. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
4545855013 Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
4545857017 Product containing precisely carbidopa 25 milligram and levodopa 100 milligram/1 each prolonged-release oral tablet (clinical drug) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet Plays role Antiparkinson therapeutic role false Inferred relationship Some
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet Has unit of presentation Tablet (unit of presentation) true Inferred relationship Some
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet Is a Product containing only carbidopa and levodopa in oral dose form (medicinal product form) true Inferred relationship Some
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet Has manufactured dose form Prolonged-release oral tablet true Inferred relationship Some
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute specifies the numerator unit for the presentation strength of a product. mg true Inferred relationship Some 1
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute specifies the denominator unit for the presentation strength of a product. Tablet (unit of presentation) true Inferred relationship Some 1
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. Levodopa (substance) true Inferred relationship Some 1
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). Levodopa (substance) true Inferred relationship Some 1
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). Carbidopa true Inferred relationship Some 2
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute specifies the numerator unit for the presentation strength of a product. mg true Inferred relationship Some 2
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute specifies the denominator unit for the presentation strength of a product. Tablet (unit of presentation) true Inferred relationship Some 2
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. Carbidopa true Inferred relationship Some 2
Inbound Relationships Type Active Source Characteristic Refinability Group

Reference Sets

Description inactivation indicator reference set

GB English

US English

Back to Start